Sai Life Sciences IPO – Review, Bid, Size, Allotment, Subscription, GMP & RHP
Last Updated Date: Jul 21, 2024Let’s have a detailed review of the company and analytics of the Sai Life Sciences IPO release date, IPO offer price, subscription, Sai Life Sciences Limited IPO allotment, grey market price, and other details like the company’s background, its financial positions, its promoters, and other related things.
| Face Value | Rs 1 |
| Price Band | Rs [●] |
| Listing At | BSE, NSE |
| Min. Order Quantity | NA Shares |
| Listing Date | NA |
| Offer for Sale | Rs Million |
| Fresh Issue | Rs 8000 Million |
| IPO Size | Rs Million |
| Tick Size | 1 |
Sai Life Sciences IPO is listed at a [●] premium. Check out the live share price by clicking on the below link.
| Live Performance – Sai Life Sciences Share Price |
Sai Life Sciences IPO – Summary
They are an innovator-focused, contract research, development, and manufacturing organization (“CRDMO”). They provide end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (“NCE”), to global pharmaceutical innovator companies and biotechnology firms.
Also, they possess both (a) discovery /contract research (“CRO”) and(b)chemistry, manufacturing, and control (“CMC”)/ contract development and manufacturing organization (“CDMO”) capabilities.
The Promoter of this company is KANUMURI RANGA RAJU, KRISHNA RAJU KANUMURI, MYTREYI KANUMURI, SAI QUEST SYN PRIVATE LIMITED, MARIGOLD PARTNERS, SUNFLOWER PARTNERS, TULIP PARTNERS AND LILY PARTNERSI. The lead manager of the issue is Kotak Mahindra Capital Company Limited, IIFL Securities Limited, Jefferies India Private Limited and Morgan Stanley India Company Private Limited, and the Registrar of this issue is KFin Technologies Limited.
Sai Life Sciences IPO Date
The opening and closing dates of Sai Life Sciences IPO are not available yet.
Sai Life Sciences IPO Subscription
| Day / Date | QIB | NII | RII | Total Subscription |
| 1st Day – | ||||
| 2nd Day – | ||||
| 3rd Day – | ||||
| Shares Offered or Net Issue |
The shares subscribed by the public will be updated here.
Sai Life Sciences IPO Allotment Status
Here, you can find the Allotment Status of this IPO.
Allotment of Equity Shares pursuant to the Fresh Issue and transfer of the Offered Shares of the Promoter Selling Shareholders pursuant to the Offer for Sale to the successful Bidders. However, the Allotment Status is not yet disclosed.
Sai Life Sciences Limited IPO Listing Date
Find the dates below on basis of allotment, refund, listing, and more:
| Basis of Allotment Finalization | – |
| Refunds Initiation | – |
| Credit of Shares to Demat Account | – |
| Share Listing Date | – |
Sai Life Sciences IPO Price Band
The face value of each share is Rs.1, but the price band of the IPO is Rs.[●]
Sai Life Sciences IPO Equity Size
This Initial Public Issue of X Equity Shares of Rs.1 each for cash at a price of Rs.[●] per equity share aggregating to Rs.[●] Million.
Sai Life Sciences IPO Share Offering
Fresh Issue: The Issue (excluding the Market Maker Reservation Portion) of [●] Equity Shares of Rs.10/ each.
Issue Size: X Equity Shares of Rs.1 each, aggregating to Rs.[●] Million
Open Free Demat Account Now!
Sai Life Sciences IPO – Live Performance
The listing date of this IPO is [●]. You can check the live performance of the IPO here, only after it is listed on exchanges.
| Live IPO Performance – Sai Life Sciences Share Price |
Sai Life Sciences IPO Grey Market Premium
The Sai Life Sciences Limited IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is Rs X.
Sai Life Sciences IPO – Company Overview
They are the fastest-growing Indian CRDMOsamong listed Indian peers in terms of revenue CAGRas well as EBITDACAGR from Financial Year 2022 to Financial Year 2024. Their CRDMO platform provides multiple entry points for them to acquire customers in the intermediate stages of their new drug discovery to commercialization journey.
They are also one of the few CRDMOsto have a unique delivery model of having research laboratories for discovery and development located near overseas innovation hubs atWatertown (Greater Boston, MA), United States (“US”)and Manchester, United Kingdom (“UK”), complemented bylarge-scale research laboratories and manufacturing facilities in cost competitive locations in India.
During the Financial Year 2024, they served more than280 innovator pharmaceutical companies,including 18 of the top 25 pharmaceutical companies (in terms of revenue for the calendar year 2023), acrossregulatedmarkets,including the US, the UK, Europe and Japan.
During the Financial Year 2024, they also provided CRO services to more than 60customers on an ongoing basis,fortheir integrateddrug discovery programs.
Sai Life Sciences IPO – Financial Statements
A quick look into the past financial performance of the company to understand its performance of the business and evaluate the growth prospectus:
Financial Summary:
| Amount (in INR & Million) | |||
| 31-Mar-24 | Mar-23 | 31-Mar-22 | |
| Total Assets |
22,751.36
|
21,866.48
|
21,642.30
|
| *Total Revenue | 14,942.69 | 12,451.05 | 8,977.41 |
| Total Expense | 13,850.35 | 12,286.97 | 8,880.46 |
| Profit After Tax | 828.09 | 99.89 | 62.26 |
Earnings per Equity Share (in Million)
| 31-Mar-24 | Mar-23 | 31-Mar-22 | |
| Basic & Diluted | 4.57 | 0.55 | 0.35 |
Further, their PAT for the period ended on March 31, 2024, March 31, 2023, and March 31, 2022, were Rs. 828.09 Million, Rs. 99.89 Million and Rs. 62.26 Million respectively.
Sai Life Sciences IPO – Promoters
The Promoter of this company is:
- KANUMURI RANGA RAJU,
- KRISHNAM RAJU KANUMURI,
- MYTREYI KANUMURI,
- SAI QUEST SYN PRIVATE LIMITED,
- MARIGOLD PARTNERS,
- SUNFLOWER PARTNERS,
- TULIP PARTNERS
- LILY PARTNERS
List of Related Parties (Key Managerial Personnel)
- Kanumuri Ranga Raju, Chairman and Whole time Director
- Krishnam Raju Kanumuri, Managing Director and Chief Executive Officer
- Mitesh Daga, Non-Executive Director
- Rajagopal Srirama Tatta, Independent Director
Sai Life Sciences IPO – Promoters Holding
- Pre-Issue Share Holding – %
- Post-Issue Share Holding – %
Sai Life Sciences IPO Offer Details or Issue Details
| Particulars | No. Of Equity Shares |
| Equity Shares Offered | Up to X Equity Shares aggregating up to Rs.[●] Million |
| of which: | |
| Issue Reserved for the Market Makers | Up to [●] Equity Shares aggregating up to Rs.[●] Million |
| Net Issue to the Public | Up to [●] Equity Shares aggregating up to Rs.[●] Million |
| Of which: | |
| Retail Investors Portion | Not less than [●] Equity Shares |
| Other than Retail Individual Investors | Not more than [●] Equity Shares |
| Equity Shares outstanding prior to the Issue | X Equity Shares |
| Equity Shares outstanding after the Issue | X Equity Shares |
Sai Life Sciences IPO Issue Object
Their Company proposes to utilize the Net Proceeds towards funding the following objects:
- Repayment/prepayment, in full or part,of all or certain outstanding borrowingsavailed by their Company; and
- General corporate purposes.
Sai Life Sciences IPO – Business Strategy
- Increase cross-selling with existing customers and win new customers
- Continue to build a strong commercial development and manufacturing portfolio of CMC capabilities
- Pursue more integrated Discovery projects to drive customer stickiness along with larger integratedDiscovery programs
- Continue to expand their existing capacityand add new technical capabilities
Sai Life Sciences IPO – Basis of Offer Price
The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.
Qualitative factors are:
- One of the largest integrated Indian CRDMOs in terms of revenue from operations for the Financial Year 2024
- CDMO platform with a diverse mix of commercial and under-development molecules
- Strategic business investments with improving profitability metrics
- Fast-growing, integrated Discovery capabilities with focus on biology, chemistry and DMPK services
The relevant quantitative factors are:
| Basic & Diluted EPS | RONW (%) | NAV (Rs.) | |
| 31-Mar-24 | 4.39 | 8.13% | 53.94 |
| 31-Mar-23 | 0.55 | 1.12% | – |
| Mar-22 | 0.35 | 0.71% | – |
Sai Life Sciences IPO: Competitive Peers
| Face Value (Rs.) | P/E | EPS (Rs.) | Return on Net Worth (%) | Revenue from operations (Rs. in Millions) | |
| Sai Life Sciences Limited | 1 | [●] | 4.39 | 8.13% |
14,651.78
|
| Listed Peers | |||||
| Divi’s Laboratories Limited | 2 |
76.78
|
60.27
|
11.79% |
78,450.00
|
| Suven Pharmaceuticals Limited | 1 |
68.78
|
11.80
|
14.64% |
10,513.54
|
Sai Life Sciences IPO Lead Managers
| Lead Managers |
|
Kotak Mahindra Capital Company Limited IIFL Securities Limited Jefferies India Private Limited Morgan Stanley India Company Private Limited |
Sai Life Sciences IPO Registrar to offer
| Registrar to the Offer |
| KFin Technologies Limited Selenium, Tower B, Plot No-31 and 32 Financial District, Nanakramguda, Serilingampally Hyderabad 500 032 Telangana, India Tel:+91 40 6716 2222 E-mail:sailifesciences.ipo@kfintech.com Investor Grievance ID:einward.ris@kfintech.com Website:www.kfintech.com Contact Person:M. Murali Krishna SEBI Registration Number:INR000000221 |
Sai Life Sciences IPO – Other Details
- Statutory Auditor – Deloitte Haskins & SellsLLP, Chartered Accountants
- Legal Counsel to the Company – Cyril Amarchand Mangaldas
- Bankers to the Company – Bank of Baroda, Kotak Mahindra Bank Limited and ICICI Bank Limited
Sai Life Sciences IPO Review by Stock Brokers
| Top Stock Brokers Review | Company Reputation | Competitive Edge | Financial Statement | Popularity Index | Promoters Reputation |
| Angel Broking | 7.5/10 | 7.4/10 | 8.5/10 | 8.1/10 | 7.1/10 |
| Sharekhan | 7.2/10 | 7.1/10 | 8.6/10 | 8.1/10 | 7.2/10 |
| Kotak Securities | 7.3/10 | 7.5/10 | 8.4/10 | 8.1/10 | 7.3/10 |
| ICICI Direct | 7.3/10 | 7.3/10 | 8.7/10 | 8.1/10 | 7.1/10 |
| IIFL | 7.5/10 | 7.2/10 | 8.8/10 | 8.0/10 | 7.1/10 |
| Edelweiss | 7.5/10 | 7.4/10 | 8.4/10 | 8.3/10 | 7.2/10 |
| Zerodha | 7.4/10 | 7.1/10 | 8.5/10 | 8.1/10 | 7.0/10 |
| 5Paisa | 7.1/10 | 7.1/10 | 8.4/10 | 8.1/10 | 7.1/10 |
| Karvy | 7.4/10 | 7.3/10 | 8.2/10 | 8.1/10 | 7.1/10 |
| Motilal Oswal | 7.1/10 | 7.1/10 | 8.6/10 | 8.3/10 | 7.2/10 |
Subscribe to Sai Life Sciences IPO
Sai Life Sciences Limited IPO News
News 1 – IPO DRHP Download
News 2 – IPO RHP Prospectus Download
Sai Life Sciences IPO Review FAQs
Check out various FAQs related to Sai Life Sciences IPO:
What is the Issue Size of Sai Life Sciences IPO?
The Company is making an initial public offer of NA equity shares. They vividly portray the aspects of the issue in this article. You can check the stats on the fresh issue, Offer for sale, and net issue.
What is the Price band of Sai Life IPO?
The price band for this particular IPO ranges between Rs NA. As far as the face value of the share is concerned, it is Rs. 1 per share.
What is the Sai Life IPO Open Date?
The opening and closing dates for this IPO have been updated. The IPO is set to open on NA, while the closing date is set at NA.
What is the Sai Life IPO Allotment Date?
They also have the news regarding the respective allotment dates of this IPO. The basis of Allotment finalization is on NA, refund initiation is on NA, credit of shares is on NA, and share listing date is on NA.
What is the Sai Life IPO Listing Date?
Shares of this company shall be listed in the exchanges NA. The date, when the listing would be done, is stagnant on NA.
Who is the Registrar of Sai Life Sciences IPO?
One of the reputed registrars is managing the issue of this IPO, i.e. KFin Technologies Limited. Their website will help you regarding the further information you are on the lookout for.
Who is the Promoter of Sai Life Sciences IPO?
Here are the promoters of this IPO – KANUMURI RANGA RAJU, KRISHNAM RAJU KANUMURI, MYTREYI KANUMURI, SAI QUEST SYN PRIVATE LIMITED, MARIGOLD PARTNERS, SUNFLOWER PARTNERS, TULIP PARTNERS AND LILY PARTNERSI. You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.
What is the GMP of Sai Life Sciences IPO?
They have obtained the GMP of this IPO and it is Rs NA. Further insights into the Kostak rate and subject to sauda or SS are as well included in this report.
Is Sai Life Sciences IPO Good for Investment?
They have further provided the financial status of the company in this article, from the past few years. You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.
What is the PAT of Sai Life Sciences Company?
They have the information on company financials, and according to that, they have the figures from the last few years to provide. PAT for the financial year 2024 in Million is 828.09, 2023 is 99.89, and 2022 is 62.26.
Calculate your return on investment!
Asset Class
ROI (Rs.)
Profit (Rs.)
Profit (%)
IPO
Equity
Savings
Real Estate
Gold
Bonds
Fixed Deposit
Mutual Fund
Featured Topics